Liver Cancer最新文献

{"title":"Antibiotics Associated with Lower Survival in Hepatocellular Cancer Patients Receiving Immune Checkpoint Inhibitors Independent of Tumor Status.","authors":"Ka Shing Cheung, Lam Lok Ka, Wai K Leung","doi":"10.1159/000528824","DOIUrl":"10.1159/000528824","url":null,"abstract":"","PeriodicalId":18156,"journal":{"name":"Liver Cancer","volume":"12 1","pages":"91-92"},"PeriodicalIF":11.6,"publicationDate":"2022-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/01/f8/lic-0012-0091.PMC9982343.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10847174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proton Beam Therapy versus Radiofrequency Ablation for Patients with Treatment-Naïve Single Hepatocellular Carcinoma: A Propensity Score Analysis.","authors":"Yuta Sekino, Ryosuke Tateishi, Nobuyoshi Fukumitsu, Toshiyuki Okumura, Kazushi Maruo, Takashi Iizumi, Haruko Numajiri, Masashi Mizumoto, Tatsuya Minami, Ryo Nakagomi, Masaya Sato, Yoshinari Asaoka, Hayato Nakagawa, Yuki Hayata, Naoto Fujiwara, Shuichiro Shiina, Kazuhiko Koike, Hideyuki Sakurai","doi":"10.1159/000528537","DOIUrl":"10.1159/000528537","url":null,"abstract":"<p><strong>Introduction: </strong>Proton beam therapy (PBT) is known to be an effective locoregional treatment for hepatocellular carcinoma (HCC). However, few comparative studies in treatment-naïve cases have been reported. The aim of this study was to compare the survival outcomes of PBT with those of radiofrequency ablation (RFA) in patients with treatment-naïve solitary HCC.</p><p><strong>Methods: </strong>Ninety-five consecutive patients with treatment-naïve HCC, a single nodule measuring ≤5 cm in diameter, and a Child-Pugh score of ≤8 who were treated with PBT at the University of Tsukuba Hospital between 2001 and 2013 were enrolled in the study. In addition, 836 patients with treatment-naïve HCC treated by RFA at the University of Tokyo Hospital during the same period were analyzed as controls. Recurrence-free survival (RFS) and overall survival (OS) were compared in 83 patient pairs after propensity score matching.</p><p><strong>Results: </strong>The 1-year, 3-year, and 5-year RFS rates were 86.6%, 49.5%, and 35.5%, respectively, in the PBT group and 59.5%, 34.0%, and 20.9% in the RFA group (<i>p</i> = 0.058); the respective OS rates were 97.6%, 77.8%, and 57.1% in the PBT group and 95.1%, 81.7%, and 67.7% in the RFA group (<i>p</i> = 0.16). Regarding adverse effects, no grade 3 or higher adverse events were noted in the PBT; however, two grade 3 adverse events occurred within 30 days of RFA in the RFA group: one hemoperitoneum and one hemothorax.</p><p><strong>Discussion: </strong>After propensity score matching, PBT showed no significant difference in RFS and OS compared to RFA. PBT can be an alternative for patients with solitary treatment-naïve HCC.</p>","PeriodicalId":18156,"journal":{"name":"Liver Cancer","volume":"12 4","pages":"297-308"},"PeriodicalIF":11.6,"publicationDate":"2022-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9a/7a/lic-0012-0297.PMC10561322.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41204561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends and Disparities in Stage-Specific Incidence of Hepatocellular Carcinoma among US Adults, 2004-2019.","authors":"Haoting Shi,&nbsp;Jingxuan Huang,&nbsp;Shi Zhao,&nbsp;Yiwen Jin,&nbsp;Rong Cai,&nbsp;Jinjun Ran","doi":"10.1159/000528374","DOIUrl":"https://doi.org/10.1159/000528374","url":null,"abstract":"<p><strong>Introduction: </strong>The aim of this study was to determine the stage-specific incidence trend of hepatocellular carcinoma (HCC) among US adults.</p><p><strong>Methods: </strong>The age-adjusted incidence rate was extracted from Surveillance, Epidemiology, and End Results database for localized, regional, and distant HCC. Trend analyses were conducted in the overall population and stratified by demographic and sociodemographic variables. The annual percentage change (APC) in 2014-2019 was estimated to determine the stage-specific incidence trend.</p><p><strong>Results: </strong>Although the incidence of localized HCC significantly declined, the incidence for regional and distant HCC plateaued in 2014-2019 (APCs, 4.4% [95% CI, -0.2% to 9.3%] and -0.7% [95% CI, -1.8% to 0.5%], respectively) with age and race/ethnicity disparities. More pronounced increases for regional and distant HCC were observed among the elderly (APCs, 8.4% [95% CI, 4.8-12.2%] and 2.2% [95% CI, 1.7-2.7%] for regional and distant HCC, respectively), non-Hispanic white individuals (APCs, 4.0% [95% CI, 2.9-5.1%] and 1.5% [95% CI, 0.7-2.4%] for regional and distant HCC, respectively).</p><p><strong>Conclusions: </strong>Disparities in incidence trends may reflect the inequalities in access to primary health care. More efforts are still in great demand for the vulnerable population.</p>","PeriodicalId":18156,"journal":{"name":"Liver Cancer","volume":"12 3","pages":"277-280"},"PeriodicalIF":13.8,"publicationDate":"2022-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8b/e1/lic-0012-0277.PMC10521315.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41106308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acknowledgement to Reviewers","authors":"","doi":"10.1159/000527592","DOIUrl":"https://doi.org/10.1159/000527592","url":null,"abstract":"<br />Liver Cancer 2022;11:583–584","PeriodicalId":18156,"journal":{"name":"Liver Cancer","volume":"64 2","pages":""},"PeriodicalIF":13.8,"publicationDate":"2022-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138512626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Contents Vol. 11, 2022","authors":"","doi":"10.1159/000528106","DOIUrl":"https://doi.org/10.1159/000528106","url":null,"abstract":"<br />Liver Cancer 2022;11:I–VIII","PeriodicalId":18156,"journal":{"name":"Liver Cancer","volume":"61 1","pages":""},"PeriodicalIF":13.8,"publicationDate":"2022-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138512634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"APPLE News","authors":"","doi":"10.1159/000528105","DOIUrl":"https://doi.org/10.1159/000528105","url":null,"abstract":"<br />Liver Cancer 2022;11:582–582","PeriodicalId":18156,"journal":{"name":"Liver Cancer","volume":"60 6","pages":""},"PeriodicalIF":13.8,"publicationDate":"2022-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138512635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immune Checkpoint Inhibitor-Related Pneumonia in Unresectable Hepatocellular Carcinoma: Two Fatal Cases under Atezolizumab plus Bevacizumab.","authors":"Kei Endo,&nbsp;Hidekatsu Kuroda,&nbsp;Takayoshi Oikawa,&nbsp;Yuma Ito,&nbsp;Tamami Abe,&nbsp;Youhei Kooka,&nbsp;Keisuke Kakisaka,&nbsp;Akio Miyasaka,&nbsp;Tamotsu Sugai,&nbsp;Takayuki Matsumoto","doi":"10.1159/000526388","DOIUrl":"https://doi.org/10.1159/000526388","url":null,"abstract":"No abstract due to Letter.","PeriodicalId":18156,"journal":{"name":"Liver Cancer","volume":"11 6","pages":"572-575"},"PeriodicalIF":13.8,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/02/0b/lic-0011-0572.PMC9801177.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10816921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum.","authors":"","doi":"10.1159/000525946","DOIUrl":"https://doi.org/10.1159/000525946","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1159/000504604.].</p>","PeriodicalId":18156,"journal":{"name":"Liver Cancer","volume":"11 6","pages":"581"},"PeriodicalIF":13.8,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b0/27/lic-0011-0581.PMC9801174.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10465484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Front & Back Matter","authors":"","doi":"10.1159/000528495","DOIUrl":"https://doi.org/10.1159/000528495","url":null,"abstract":"","PeriodicalId":18156,"journal":{"name":"Liver Cancer","volume":"17 1","pages":""},"PeriodicalIF":13.8,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78269181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Atezolizumab plus Bevacizumab versus Sorafenib for Unresectable Hepatocellular Carcinoma: Results from Older Adults Enrolled in the IMbrave150 Randomized Clinical Trial.","authors":"Daneng Li,&nbsp;Han Chong Toh,&nbsp;Philippe Merle,&nbsp;Kaoru Tsuchiya,&nbsp;Sairy Hernandez,&nbsp;Wendy Verret,&nbsp;Alan Nicholas,&nbsp;Masatoshi Kudo","doi":"10.1159/000525671","DOIUrl":"https://doi.org/10.1159/000525671","url":null,"abstract":"<p><strong>Introduction: </strong>The efficacy of systemic first-line treatments in older adults with unresectable hepatocellular carcinoma (HCC) has not been well-studied. We compared the safety and efficacy of atezolizumab plus bevacizumab versus sorafenib as a first-line treatment in younger versus older patients with unresectable HCC.</p><p><strong>Methods: </strong>This global, phase 3, open-label, randomized clinical trial (IMbrave150) recruited patients aged ≥18 years with locally advanced metastatic or unresectable HCC, an Eastern Cooperative Oncology Group performance status score of 0 or 1, and Child-Pugh class A liver function who had not previously received systemic therapy for liver cancer. Patients received either 1,200 mg atezolizumab plus 15 mg/kg bevacizumab intravenously every 3 weeks or 400 mg sorafenib orally twice daily until loss of clinical benefit or unacceptable toxicity. Primary endpoints were overall survival (OS) and progression-free survival (PFS). Secondary outcomes were the incidence of adverse events and time to deterioration of patient-reported outcomes (PROs). This subgroup analysis evaluated safety and efficacy endpoints in patients <65 years, ≥65 to <75 years, and ≥75 years.</p><p><strong>Results: </strong>Of 501 patients, 165 patients were randomized to sorafenib and 336 were randomized to atezolizumab plus bevacizumab (175 patients <65 years; 106 patients ≥65 to <75 years; 55 patients ≥75 years). Across all age groups, patients receiving atezolizumab plus bevacizumab had longer median OS (<65: 18.0 vs. 12.2 months [HR, 0.57; 95% CI: 0.40-0.82]; ≥65 to <75: 19.4 vs. 14.9 months [HR, 0.80; 95% CI: 0.52-1.23]; ≥75: 24.0 vs. 18.0 months [HR, 0.72, 95% CI: 0.37-1.41]) and PFS than those receiving sorafenib. Time to deterioration for multiple PROs was delayed for patients receiving atezolizumab plus bevacizumab, including older adults. There were no clinically meaningful differences in toxicity between age groups.</p><p><strong>Conclusion: </strong>Atezolizumab plus bevacizumab is safe and effective in adults <65, ≥65 to <75, and ≥75. Treatment was well-tolerated even in elderly patients.</p>","PeriodicalId":18156,"journal":{"name":"Liver Cancer","volume":"11 6","pages":"558-571"},"PeriodicalIF":13.8,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/fd/c5/lic-0011-0558.PMC9801180.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10816922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}